After proposing an undisclosed alternative price, Clovis Oncology Inc., of Boulder, Colo., got the approval of the U.K.'s National Institute for Health and Care Excellence (NICE) for coverage of its ovarian cancer drug Rubraca (rucaparib) under the Cancer Drugs Fund (CDF) while the company continues to collect long-term overall survival data. The twice-daily tablet will be available immediately under the fund for women with relapsed ovarian, fallopian tube or peritoneal cancer that has responded to platinum-based chemotherapy. NICE's decision is a reversal from an initial recommendation in which it said "uncertainties in the evidence and the price of rucaparib meant it could not be recommended for routine use on the [National Health Service]." In clinical trials, Rubraca prevented cancer progression for twice as long as the placebo treatment – a median of 10.8 months in the rucaparib group compared with 5.4 months in the placebo group. "However, it is not known how this will translate into overall extended life expectancy due to incomplete trial data," NICE said. NICE recently recommended CDF coverage for two other ovarian cancer drugs – Zejula (niraparib, Glaxosmithkline plc) and Lynparza (olaparib, Astrazeneca plc/Merck & Co. Inc.).